胸腔病例（三五四）特發性性肺纖維化

10.6666/ClinMed.201811_82(5).0127

林佑容；柯信國

特發性肺纖維化（idiopathic pulmonary fibrosis, IPF） ； 尋常性間質性肺炎（usual interstitial pneumonia, UIP） ； 肺部纖維化（pulmonary fibrosis）

臨床醫學月刊

82卷5期（2018 / 11 / 30）

688 - 695

繁體中文

特發性肺纖維化（idiopathic pulmonary fibrosis, IPF）是一種未知病因的慢性、進展性肺間質纖維變化，在影像及病理切片以尋常性間質性肺炎（Usual interstitial pneumonia, UIP）表現，多發生於60-70歲人口，以男性居多。臨床症狀包含隨時間而進展的活動性呼吸困難及乾咳。近年來，Nintedanib及Pirfenidone這兩種藥物證實能減緩肺功能中吐氣肺容積下降、改善生活品質及減少疾病急性惡化。本病例為一87歲男性經肺部高解像度電腦斷層（HRCT）檢查為UIP並排除自體免疫疾病後診斷IPF，接受Nintedanib治療及治療中慢性阻塞性肺病急性惡化之相關處置。

1. (2014).Nintedanib. US Food and Drug Administration (FDA) approved product information. US National Library of Med 2014..
2. (2014).Pirfenidone. US Food and Drug Administration (FDA) approved product information. US National Library of Med 2014..
3. Bateman, ED,Turner-Warwick, M,Adelmann-Grill, BC(1981).Immunohistochemical study of collagen types in human foetal lung and fibrotic lung disease.Thorax,36,645-653.
4. Collard, HR,Ryerson, CJ,Corte, TJ(2016).Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.Am J Respir Crit Care Med,194,265-275.
5. Corte, TJ,Copley, SJ,Desai, SR(2012).Significance of connective tissue disease features in idiopathic interstitial pneumonia.Eur Respir J,39,661-668.
6. David, JL,Fernando, JM(2018).Idiopathic Pulmonary Fibrosis.N Engl J Med,378,1811-1823.
7. du Bois, RM,Weycker, D,Albera, C(2011).Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.Am J Respir Crit Care Med,184,459-466.
8. Lai, CC,Wang, CY,Lu, HM(2012).Idiopathic pulmonary fibrosis in Taiwan - a population-based study.Respir Med,106,1566-1574.
9. Ley, B,Collard, HR,King, TE, Jr(2011).Clinical course and prediction of survival in idiopathic pulmonary fibrosis.Am J Respir Crit Care Med,183,431-440.
10. Lynch, DA,Sverzellati, N,Travis, WD(2018).Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.Lancet Respir Med,6,138-153.
11. Nakamura, Yutaro,Suda, Takafumi(2015).Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations.Clin Med Insights Circ Respir Pulm Med,9,163-171.
12. Natsuizaka, M,Chiba, H,Kuronuma, K(2014).Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences.Am J Respir Crit Care Med,190,773-779.
13. Navaratnam, V,Fleming, KM,West, J(2011).The rising incidence of idiopathic pulmonary fibrosis in the UK.Thorax,66,462-467.
14. Raghu, G,Collard, HR,Egan, JJ(2011).An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.Am J Respir Crit Care Med,183,788-824.
15. Richeldi, L,Costabel, U,Selman, M(2011).Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.N Engl J Med,365,1079-1087.
16. Richeldi, L,du Bois, RM,Raghu, G(2014).Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.N Engl J Med,370,2071-2082.
17. Richeldi, L,du, Bois, RM,Raghu, G.(2014).Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis.N Engl J Med,370,2071-2082.
18. Scotton, CJ,Chambers, RC(2007).Molecular targets in pulmonary fibrosis: the myofibroblast in focus.Chest,132,1311-1321.
19. Selman, M,King, TE,Pardo, A(2001).Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy.Ann Intern Med,134,136-151.
20. Wells, AU(2013).Managing diagnostic procedures in idiopathic pulmonary fibrosis.Eur Respir Rev,22,158-162.